Form 4: Regeneron Director Acquires Shares and Stock Options

Regeneron Pharmaceuticals director David P. Schenkein acquired 166 shares of common stock and 1,958 stock options on January 2, 2025.

Summary

• David P. Schenkein, a director at Regeneron Pharmaceuticals, acquired 166 shares of common stock on January 2, 2025.
• These shares were acquired as time-based vesting restricted stock units, each representing a right to receive one share of common stock.
• Schenkein also acquired 1,958 non-qualified stock options on the same date, with an exercise price of $719.37 per share.
• A portion of these stock options will become exercisable on the date of the first annual shareholder meeting following the grant date, and the remainder will become exercisable on the first anniversary of the grant date.
• The stock options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it indicates alignment of interests between management and shareholders. There is no negative information.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future performance.
• The vesting schedule of the stock options aligns the director's interests with the long-term success of the company.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It reflects standard compensation practices for directors.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of compensation for directors in the pharmaceutical industry.
• The vesting schedule described is typical, aligning director compensation with company performance over time.
• Companies like Amgen, Gilead, and Biogen also use similar equity-based compensation for their directors.

Stakeholder Impact

• The acquisition of shares and stock options by a director can be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Regeneron, stock options, share acquisition, insider trading, director, David P. Schenkein, equity, vesting